The core herpes simplex-1 fusion complex drives cell-to-cell spreading of pathological Tau

Technical Summary: The Core Herpes Simplex-1 Fusion Complex Drives Cell-to-Cell Spreading of Pathological Tau

Problem Statement
Neurodegenerative diseases, notably Alzheimer's disease (AD), are defined by the pathological aggregation of the host-encoded protein Tau into amyloid fibrils. A critical feature of these diseases is the ability of pathologic Tau aggregates to spread intercellularly, driving disease progression. However, the precise mechanisms governing this cell-to-cell dissemination remain ill-defined. Concurrently, mounting epidemiological and biological evidence links Herpes Simplex Virus-1 (HSV-1) to the etiology of AD. While HSV-1 typically replicates in epithelial cells and establishes lifelong latency in the nervous system, AD brains exhibit elevated expression of structural viral proteins during the quiescent latent state, despite the absence of active virus production. This raises the question of whether latent HSV-1 components contribute to the propagation of proteopathic seeds.

Methodology
To investigate the hypothesis that HSV-1 glycoproteins facilitate the intercellular spreading of Tau aggregates, the authors employed cellular models to express specific viral components. The study focused on the HSV-1 core fusion complex, a set of glycoproteins essential for viral entry and direct cell-to-cell transmission. The researchers tested whether the expression of this complex alone was sufficient to promote the dissemination of Tau aggregates between cells. Furthermore, the study utilized cerebrospinal fluid (CSF) samples from patients with HSV-1 encephalitis containing anti-HSV-1 antibodies to assess their capacity to neutralize viral infection, block viral cell-to-cell transmission, and inhibit the propagation of pathological Tau.

Key Results
The study demonstrates that the expression of the HSV-1 core fusion complex is sufficient to promote the dissemination of Tau aggregates between cells in the absence of a full viral infection cycle. This suggests that the structural machinery used by the virus for cell-to-cell transmission can be co-opted to spread proteopathic seeds. Additionally, the research found that anti-HSV-1 antibodies present in the CSF of patients with HSV-1 encephalitis effectively neutralize viral infection and block viral cell-to-cell transmission. Crucially, these antibodies were also shown to inhibit the propagation of pathological Tau, indicating a mechanistic link between viral fusion activity and Tau spread.

Significance and Claims
The paper posits that latent HSV-1 infection of the brain may contribute to the progression of neurodegenerative diseases by facilitating the intercellular spread of pathological Tau through the expression of viral fusion complexes. The findings suggest that the structural viral proteins present in the latent state, rather than active viral replication, may drive this pathological dissemination. Consequently, the study proposes that antiviral antibodies, which can neutralize these fusion mechanisms, may represent a potential therapeutic strategy for interrupting the spread of Tau and slowing disease progression.